ACAD Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
ACADIA Pharmaceuticals Inc (ACAD) is not a strong buy at the moment for a beginner investor with a long-term strategy. The stock is currently in a bearish trend, with recent price declines and no immediate positive trading signals. While the company's financial performance and analyst sentiment show long-term potential, the lack of immediate catalysts and the recent negative news sentiment suggest waiting for a better entry point.
The stock is in a bearish trend with MACD below zero and negatively expanding, RSI at 34.514 in the neutral zone, and bearish moving averages (SMA_200 > SMA_20 > SMA_5). The price is near the S1 support level of 22.513, with resistance at 23.766.
Strong financial performance in Q4 2025 with revenue up 9.39% YoY, net income up 90.32% YoY, and EPS up 84.88% YoY. Analysts have raised price targets, with several firms maintaining Buy or Outperform ratings, citing strong guidance and pipeline momentum.
Recent negative news about the CHMP's opinion on trofinetide for Rett syndrome and a 7.13% drop in share price. The stock has also faced a 4.23% regular market decline and a 2.18% pre-market decline. Technical indicators are bearish, and there are no significant hedge fund or insider trading trends.
In Q4 2025, revenue increased to $283.99M (up 9.39% YoY), net income increased to $273.57M (up 90.32% YoY), and EPS increased to 1.59 (up 84.88% YoY). However, gross margin slightly dropped to 90.77% (down -0.91% YoY).
Analysts are generally positive on ACAD, with multiple firms raising price targets. JPMorgan sees the stock as well-positioned for upside, and TD Cowen highlights strong guidance and pipeline potential. However, BofA and Stifel maintain Neutral and Hold ratings, respectively, citing cautious optimism.
